Core - Cancer Pharmacology

核心 - 癌症药理学

• 批准号: 7746368
• 负责人: EDWARD J BENZ
• 金额: $ 32.39万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7746368
• 关键词: Biological; Biological Assay; Cancer Center Support Grant; Clinical; Dana-Farber Cancer Institute; Data; Development; Drug Combinations; Drug Kinetics; Evaluation; Goals; Investigation; Liquid substance; Pharmaceutical Preparations; Pharmacodynamics; Phase; Phase II Clinical Trials; Research Personnel; Resources; Services; Treatment Protocols; analytical method; cancer pharmacology; cancer therapy; chemotherapeutic agent; design; pre-clinical; preclinical evaluation

The Cancer Pharmacology Core provides DF/HCC investigators with the necessary expertise and resources to design and undertake pharmacokinetic studies in the context of phase I and phase II clinical trials, and preclinical investigations. The core has the ability to implement and validate previously developed analytical methods to quantify drugs and their metabolites in biological fluids as well as the capability to modify or develop entirely new assays when warranted. The core also offers comprehensive analysis of pharmacokinetic data as an additional service, including the estimation of pharmacokinetic parameters and identifying their relationship to pathophysiological variables and pharmacodynamic effects.

癌症药理学核心为DF/HCC调查人员提供必要的专业知识和 在第一阶段和第二阶段设计和进行药代动力学研究的资源 临床试验和临床前研究。核心具有实施和验证的能力 以前开发了分析方法，用于在生物流体中量化药物及其代谢物为 以及保证后修改或开发全新测定的能力。核心也提供 将药代动力学数据作为额外服务的全面分析，包括估计 药代动力学参数并确定其与病理生理变量的关系 药效效应。